The animal health market size was exhibited at USD 66.35 billion in 2024 and is projected to hit around USD 158.52 billion by 2034, growing at a CAGR of 9.1% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 72.39 Billion |
| Market Size by 2034 | USD 158.52 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 9.1% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Product, Distribution Channel, Animal Type, End use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | Zoetis; Ceva Santé Animale; Merck & Co., Inc.; Vetoquinol S.A.; Boehringer Ingelheim GmbH; Elanco; Virbac; Mars Inc.; Dechra Pharmaceuticals plc; IDEXX Laboratories, Inc. |
Factors driving the market growth include rising animal health expenditure, the prevalence of diseases in animals, concerns over zoonoses, initiatives by key companies, uptake of pet insurance, and pet humanization. For instance, in January 2024, Merck opened a new manufacturing facility to produce companion animal vaccines in Boxmeer, Netherlands, to meet increased global customer demand.
The market remained resilient during the COVID-19 public health emergency owing to a surge in pet adoption, increasing pet humanization, and growing concerns over zoonoses. Some of the negative impacts of the pandemic include decreased sales, supply chain disruptions, and operational hurdles due to changing regulations worldwide. On the other hand, the trend for telemedicine witnessed significant growth during the pandemic. Online channels such as e-commerce emerged as pet owners' most preferred distribution channels for purchasing vet products and pet food.
The market was also impacted by macroeconomic headwinds such as inflation, foreign exchange rate fluctuations, and geopolitical conflict during H2 2022. Zoetis, for instance, reported a decrease in revenue growth by 3% in Q1 and Q2 and 4% in Q3 in 2022. The company reported an overall decrease of 4% in revenue growth in the year 2022. Elanco’s revenue growth was negatively impacted by the change in foreign exchange rates, with a 4% decrease in H1 and a 5% decrease in the Q3 results in 2022. On the other hand, Vimian, based in Sweden, reported a positive impact on revenue growth, estimated at 2.5% in Q1, 4.9% in Q2, and 5.6% in Q3 2022.
Animal Health Market Trends
The market is characterized by a high degree of innovation in terms of products. Multiple segments within the market are witnessing rapid developments and investments such as biologics, regenerative medicine, monoclonal antibodies, pharmaceuticals, software, diagnostic products, etc. In November 2024, Boehringer Ingelheim for instance received clearance from the European Commission for SENVELGO— its first oral liquid medication for cats with diabetes.
The market is also undergoing some consolidation as larger companies acquire other market players to boost their portfolios and capabilities. In August 2024, Mars Inc. entered into an agreement to acquire a European Veterinary Reference Laboratory called SYNLAB Vetfrom SYNLAB Group. This complemented its Petcare division’s existing footprint in the full-service veterinary diagnostics business in Europe.
The market is subject to diverse regulations. The development and manufacturing of medicines is strictly monitored by government agencies such as FDA while the regulations for veterinary diagnostic and other products are comparatively lax.Regulatory approval processes can be lengthy and complex, creating barriers to entry for new companies. This often results in established players holding notable animal health market share, as they have the resources and experience to navigate regulatory hurdles.
Notable threat of product substitutes may restrain the growth of the market. Point-of-care diagnostic tools and at-home testing kits for example are becoming more common, offering alternatives to traditional veterinary diagnostic procedures. These alternatives provide convenience for pet owners and farmers. Also, herbal and natural remedies, including supplements and extracts, are often considered substitutes for conventional pharmaceuticals. They are perceived by some pet owners and farmers as more natural alternatives with potentially fewer side effects.
Regional expansion in the market is estimated to be moderate to high owing to several initiatives undertaken by key companies. In October 2021, Boehringer Ingelheim invested EUR 100 million in a Lyon-Jonage based veterinary public health (VPH) strategic production center in France. This added to the company’s animal vaccines capacity for emerging and transboundary diseases as well as furthered its footprint in the Lyon region.
By product, the pharmaceutical segment dominated the market with a share of about 43% in 2024.It is estimated to retain its dominant position throughout the forecast period due to consistent advancements in veterinary drugs. Pharmaceuticals primarily include anti-inflammatory drugs, parasiticides, antibiotics, and others. There is an increasing awareness and concern among pet owners, farmers, and animal caretakers about the importance of animal health. This heightened awareness combined with product development by key companies drives the demand for pharmaceuticals that address various health conditions, from common infections to chronic diseases.
The others segment comprising veterinary telehealth, veterinary software, and livestock monitoring solutions is expected to grow the fastest at a rate of about 12% in the near future. The COVID-19 pandemic in particular led to a surge in the adoption of telehealth Apps and software to facilitate patient and veterinarian visits virtually. Many new players have entered the market since 2020 while existing companies enhanced their service offerings. In May 2024, Walmart for instance partnered with a veterinary telehealth provider— Pawp to offer Walmart+ customersaccess to veterinary professionals via video or text.
In 2024, the production animal segment dominated the market and accounted for the largest revenue share. The substantial segment share results from increased concern for food safety and sustainability among end users as well as market stakeholders such as government healthcare organizations. As livestock farming modernizes to suffice the food demand of the global population, market stakeholders are increasingly adopting precision livestock farming techniques, biosecurity measures, and periodic programmes such as annual vaccinations. This is expected to contribute to the continued dominance of the segment over the forecast period.
The companion animal segment is expected to grow at a lucrative rate during the forecast period. This is owing to increasing uptake of pet insurance, pet humanization, expenditure on pets, and medicalization rate. The trend of humanizing companion animals, considering them as integral family members, has led to increased spending on their healthcare. This trend includes a willingness among pet owners to invest in advanced veterinary pharmaceuticals and medical treatments. Pet owners are thus increasingly seeking medical treatments, preventive care, and pharmaceutical solutions to ensure the health and well-being of their animals.
The hospital/ clinic pharmacy segment accounted for the largest revenue share in 2024 in terms of distribution channel.The increasing number of hospital pharmacies and high procedural volume have supported segment growth. Retail channels and e-commerce platforms also accounted for a significant share of the total market. The e-commerce segment is anticipated to witness fastest growth rate throughout the forecast period. This can be attributed to various advantages such as increased convenience for patients not willing to purchase medicines from retail or hospital pharmacies.
Moreover, e-commerce channels also facilitate a consistent supply of drugs, and as medications, these can be preordered. Benefits such as these are anticipated to accentuate the demand for e-commerce throughout the forecast period. With the help of online pharmacies, order procurement and tracking become easy as associated Supply Chain Management (SCM) eliminates other market intermediaries of the delivery channel. This reduces overall costs, thereby increasing customer preference. Retail pharmacies for animal health products are expected to grow moderately throughout the forecast period.
By end use, the veterinary hospitals and clinics segment accounted for the largest revenue share 80.0% of the market in 2024. This is due to large number of hospitals and clinics across the globe and highest footfall of patients at these care centers. The facilities have a wide range of treatment and diagnostic options which is a key driver for this segment. Certain vaccines are only available in accredited veterinary hospitals and clinics, which is responsible for increasing the share of this end-user segment.
The Point-of-care Testing/In-house Testing segment on the other hand, is projected to grow at the highest CAGR from 2024 to 2034. An increase in the incidences of zoonotic diseases is expected to drive the demand for diagnostic procedures, which will drive the point-of-care testing/ in-house testing segments in the coming years. The increase in initiatives to create awareness among companion animal owners about the benefits and value of preventive care in pets is a key contributing factor to in-house animal health testing. Tests such as ELISA have been proven effective point-of-care tests for heartworm diagnosis.
By region, North America held the highest share of about 32% of the market in 2024. This can be attributed to the wide range of definitive measures adopted by government and animal welfare organizations that consistently work to improve animal health. Asia Pacific Region is anticipated to grow the fastest a rate of over 10% in the coming years. This is due to growing investments in animal healthcare by prominent players and their efforts to commercialize branded and generic medicines at competitive prices. The animal health market of Europe also held significant share supported by increasing prevalence of diseases in animals and growing veterinary care expenditure.
India Animal Health Market Trends
Animal Health Market of India is witnessing a surge in demand for veterinary products and services to address existing and emerging diseases in animals. Global regulatory initiatives promoting responsible antibiotic use and the growing significance of animal welfare standards are shaping the industry. Additionally, the market is experiencing heightened investments in R&D, portfolio acquisition etc., fostering the market growth in the country. For example, in December 2024, Zenex— an Indian animal health company acquired Ayurvet— a company providing ayurvedic and herbal medicines, topical treatments, and feed supplements for production and companion animals. This expanded the portfolio of Zenex and strengthened its geographic access. Overall, the Animal Health Market in India reflects a dynamic landscape responding to evolving consumer preferences, technological advancements, and regulatory imperatives.
Australia Animal Health Market Trends
The Animal Health Market in Australia is characterized by a robust and sophisticated industry addressing the health and well-being of both pets and livestock. With a strong emphasis on preventive care, the market witnesses a growing demand for biologics such as vaccines as well as health supplements. The market is influenced by a rising trend of pet humanization, driving investments in high-quality veterinary medicines, diagnostics, and healthcare services. Livestock management is marked by a focus on biosecurity measures and sustainable practices, leading to increased adoption of innovative solutions.Regulatory frameworks ensure product safety and efficacy, while ongoing R&D initiatives contribute to the introduction of novel therapies.The industry reflects a commitment to animal welfare, aligning with global standards, and the market is poised for further growth through technological advancements and an evolving understanding of the interconnectedness of animal and human health.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the animal health market
Animal Type
Product
Distribution Channel
End-use
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers